Synaptogenix announces reverse stock split to maintain nasdaq listing

Common stock will begin trading on split-adjusted basis on april 5, 2024 new york , april 3, 2024 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. the reverse stock split will become effective at 5:00 p.m.
SNPX Ratings Summary
SNPX Quant Ranking